Results 211 to 220 of about 18,037 (235)
Some of the next articles are maybe not open access.
Mineralocorticoid Receptor Antagonists: An Overview of History and Evolution
Journal of The Association of Physicians of IndiaMineralocorticoid receptor antagonists (MRAs) have significantly evolved since the introduction of the first steroidal MRA, spironolactone, in the 1950s. Initially discovered for treating hypertension and heart failure (HF), the clinical applications of MRAs have been expanded to chronic kidney disease (CKD) and diabetic nephropathy.
B C, Kalmath +13 more
openaire +2 more sources
Mineralocorticoid receptor antagonists (MRAs)
Abstract The final process in the renin–angiotensin–aldosterone system (RAAS) is the production of the mineralocorticoid aldosterone in the adrenal glands. Aldosterone has an important role in the pathophysiology of heart failure, and concentrations of aldosterone are 20-fold higher in patients with HF compared to normal individuals ...Roy S. Gardner +3 more
openaire +1 more source
Steroidal and Non-Steroidal Mineralocorticoid Receptor Antagonists in Cardiorenal Medicine
European Heart Journal, 2021Faiez Zannad +2 more
exaly
Novel Non-Steroidal Mineralocorticoid Receptor Antagonists in Cardiorenal Disease
British Journal of Pharmacology, 2022Ulrich Kintscher +2 more
exaly
Role of Mineralocorticoid Receptor Antagonists in Kidney Diseases
Drug Development Research, 2021Mukul R Jain +2 more
exaly
Non-Steroidal Mineralocorticoid Receptor Antagonists in Cardiorenal Disease
European Heart Journal, 2022Arjun K Pandey +2 more
exaly